Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial
This week, we will discuss the ongoing saga of blood pressure targets in patients with hypertension. This time its ESPRIT (Effects of Intensive Systolic Blood Pressure Lowering Treatment in Reducing Risk of Vascular Events) making a case for case for intensive BP control in most hypertensive individuals, including those with a history of diabetes and stroke.
Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial
#TenTweetNephJC returns in 2023! Catch-up rapidly with the biggest trials in nephrology.
— Nephrology Journal Club (@NephJC) January 20, 2023
Up first is NefIgArd.
We all say we hate steroids, but really we love their efficacy but hate their side-effects, right?
IgA nephropathy is again the subject of a steroid trial🧵 pic.twitter.com/sh0xtKPhsP